BIM
NGNE icon

Bogle Investment Management’s Neurogene NGNE Stock Holding History

Bogle Investment Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-890
Closed -$203K – 384
2020
Q1 		$203K Buy
+890
New +$183K 0.02% 257

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Bogle Investment Management's NGNE Position: Q2 2020 in Review

Bogle Investment Management sold out of Neurogene (NGNE) in Q2 2020, closing a stake of 890 shares — an estimated $203K sold.

Bogle Investment Management first reported a position in NGNE in Q1 2020 and held it in 1 quarter. The position peaked at $203K in Q1 2020. 74 funds tracked by Wall St. Rank hold NGNE as of Q2 2020.

  • Bogle Investment Management reported no remaining Neurogene position as of Q2 2020 after selling out during the quarter.
  • Bogle Investment Management sold 890 Neurogene shares in Q2 2020, an estimated $203K.
  • Bogle Investment Management first reported a position in Neurogene in Q1 2020 and held it in 1 quarter.
  • Bogle Investment Management's Neurogene position peaked at $203K in Q1 2020.
  • 74 funds tracked by Wall St. Rank held Neurogene as of Q2 2020.

Based on Bogle Investment Management's 13F filing for Q2 2020, filed 13 Aug 2020.